Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olive pollen allergen immunotherapy preparation
- Development stage
- Unknown
- Lead developer
- ALK Abelló
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Olive pollen allergen immunotherapy preparation (marketed as AVANZ Olive) is an allergen-specific immunotherapy (AIT) developed by ALK-Abelló (and its subsidiary ALK-Scherax Arzneimittel) to induce immunological tolerance to olive (*Olea europaea*) pollen allergens in sensitized patients. Formulated as a standardized allergen extract adsorbed on aluminium hydroxide, it is administered subcutaneously to treat olive pollen allergy, allergic rhinitis, and associated allergic rhinoconjunctivitis. The therapy works by modulating the immune system's type 2 inflammatory response, shifting the immune profile toward tolerance through the induction of regulatory T (Treg) cells and allergen-specific IgG4 antibodies, thereby reducing allergic symptoms and immediate skin reactivity upon allergen exposure.
- Brand names
- AVANZ Olive
- Other names
- AVANZ Olea europaeaOlea europaea pollen extractOlive pollen AIT preparationolive pollen extractstandardized olive pollen allergen extract
02
Targets
BCR (Olive pollen allergen-specific B-cell receptors)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on olive pollen allergen immunotherapy preparation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olive pollen allergen immunotherapy preparation.